Tenax Therapeutics expands equity pool by 400k shares; CMO shifts to part-time

TENAX THERAPEUTICS, INC.

Stockholders approved Amendment No. 1 to 2022 Stock Incentive Plan, increasing authorized shares to 400,688.
CMO Dr. Stuart Rich will work 3 days/week from June 15, 2024; annual base salary of $333,900 prorated to 60%.
Board elected; auditor Cherry Bekaert LLP ratified. Next advisory vote on exec compensation set for 2025 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.